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BoOBJECTIVES This study sought to assess the prevalence and clinical impact of silent diabetes and pre-diabetes in
“nondiabetic” percutaneous coronary intervention (PCI) all-comers.
BACKGROUND Patients with undetected and thus untreated (silent) diabetes may have higher event risks after PCI
with contemporary drug-eluting stents (DES).
METHODS The BIO-RESORT Silent Diabetes study, performed at Thoraxcentrum Twente, is a substudy of the ran-
domized multicenter BIO-RESORT (BIOdegradable Polymer and DuRable Polymer Drug-eluting Stents in an All COmeRs
PopulaTion) trial (NCT01674803). Patients underwent oral glucose tolerance testing (OGTT), and assessment of
glycosylated hemoglobin with fasting plasma glucose. Primary endpoint was a composite of cardiac death, target vessel–
related myocardial infarction, or target vessel revascularization at 1 year.
RESULTS Of the 988 participants, OGTT detected silent diabetes in 68 (6.9%), pre-diabetes in 133 (13.3%), and normal
glucose metabolism in 788 (79.8%). Patients with silent diabetes had higher primary endpoint rates (13.2% vs. 7.6% vs.
4.8%; p < 0.001; silent diabetes vs. normal: hazard ratio: 4.2; 95% confidence interval: 1.9 to 9.2). Differences were
driven by myocardial infarction (p < 0.001) which occurred mostly <48 h. Based on glycosylated hemoglobin and fasting
plasma glucose, silent diabetes was found in 33 (3.3%) patients, pre-diabetes in 217 (22.0%) patients, and normal
glucose metabolism in 738 (74.7%) patients; primary endpoint rates were similar to OGTT-based analyses (12.1% vs.
5.5% vs. 3.1%; p ¼ 0.01). Multivariate analyses demonstrated that abnormal glucose metabolism by either diagnostic
approach, present in 330 (33.4%) patients, independently predicted adverse event risk (hazard ratio: 2.2; 95% confi-
dence interval: 1.2 to 4.2).
CONCLUSIONS Abnormal glucose metabolism was detected in 1 of 3 “nondiabetic” PCI patients and was independently
associated with up to 4-fold higher event risks. Future intervention trials should determine whether meaningful
benefits accrue from routine glycemia testing in such patients. (J Am Coll Cardiol Intv 2018;11:448–59)
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449AB BR E V I A T I O N S
AND ACRONYM S
DES = drug-eluting stent(s)
DM = diabetes mellitus
FPG = fasting plasma glucose
IFG = impaired fasting glucose
IGT = impaired glucose
tolerance
MI = myocardial infarction
OGTT = oral glucose tolerance
testing
PCI = percutaneous coronary
interventionD iabetes mellitus (DM) is associated withadverse outcome in the general populationand even more so in patients with cardio-
vascular disease (1). Many patients with coronary ar-
tery disease share risk factors with the metabolic
syndrome and are for that reason at risk of developing
diabetes (2). Diabetic patients, who represent an
increasing proportion of all patients referred for
percutaneous coronary intervention (PCI), are at a
higher adverse events risk (3,4) and continue to
show a higher mortality despite the development of
newer-generation drug-eluting stents (DES) with
improved biocompatibility (4–7). Traditionally, the
diagnosis of diabetes or pre-diabetes (impaired
glucose tolerance [IGT] and impaired fasting glucose
[IFG])—an early stage of diabetes—is made based on
increased fasting plasma glucose (FPG) levels or oral
glucose tolerance testing (OGTT) or elevated glycosy-
lated hemoglobin (HbA1c) (8–10).SEE PAGE 460A substantial proportion of patients have unde-
tected and thus untreated (silent) diabetes, which
may lead to more cardiovascular complications.
Abnormal glucose metabolism with its chronic hy-
perglycemic state leads to dyslipidemia, hypercoag-
ulability, increased atheroma burden, vessel wall
inflammation, and vulnerable plaques (7,11). Previous
post hoc analyses of data from the TWENTE (The
Real-World Endeavor Resolute versus Xience V Drug-
Eluting Stent Study in Twente) trial, which assessed
PCI with newer-generation DES in a broad patient
population (12), suggested a relation between unde-
tected diabetes and outcome following PCI (13). In
addition, based on data from the EUROASPIRE IV
(European Action on Secondary and Primary Preven-
tion by Intervention to Reduce Events) study (14), it
was recently recommended that all patients with
cardiovascular disease should undergo OGTT, which
is considered by some, but not all (15), a standard for
detecting diabetes (8,9,14,16).
Therefore, in the present BIO-RESORT (BIOde-
gradable Polymer and DuRable Polymer Drug-eluting
Stents in an All COmeRs PopulaTion) Silent Diabetes
study, we used OGTT and HbA1c with FPG to pro-
spectively assess the prevalence of silent diabetes
and pre-diabetes in a population of PCI all-comerBoston Scientific, and Medtronic. Dr. Sattar has received personal fees from
Ingelheim, Novo Nordisk, Eli Lilly and Co., and Janssen; has received rese
AstraZeneca; and has received personal fees from AstraZeneca. All other au
relevant to the contents of this paper to disclose. Drs. von Birgelen and Kok
Manuscript received August 22, 2017; revised manuscript received October 2patients. In addition, we investigated the
potential impact of abnormal glucose meta-
bolism on 1-year clinical outcome.
METHODS
STUDY DESIGN, PATIENTS, AND PROCED-
URES. The BIO-RESORT Silent Diabetes
study, performed at Thoraxcentrum Twente,
is a pre-specified, prospective substudy of the
randomized multicenter BIO-RESORT trial
(17), registered with ClinicalTrials.gov
(NCT01674803). The randomized trial
enrolled all-comer patients undergoing PCI
procedures that reflected daily clinical practice. Pa-
tients were treated with 1 of 3 contemporary DES:
Synergy everolimus-eluting stent (Boston Scientific,
Natick, Massachusetts), Orsiro sirolimus-eluting stent
(Biotronik, Bülach, Switzerland), or Resolute Integrity
zotarolimus-eluting stent (Medtronic, Santa Rosa,
California). As recently reported, 1-year clinical
outcome did not differ significantly between the 3
stents (17).
Patients without known diabetes, treated at Thor-
axcentrum Twente in Enschede, the Netherlands,
were invited to participate in the substudy. A total of
988 of 1,889 invited patients agreed to participate.
Four to 6 weeks after the index procedure, OGTT was
done at an outpatient setting by experienced staff
from the central laboratory department. After 8 h of
fasting, blood samples were taken to measure base-
line FPG and HbA1c; patients then drank 75 g glucose
dissolved in 300 ml water within 5 min (18). To ensure
optimal accuracy of the test, patients remained at the
clinic and were instructed not to perform any energy-
consuming activities during the next 2 h. Subse-
quently, an additional blood sample was taken to
measure the 2-h glucose level (Hexokinase, Roche
Diagnostics, Almere, the Netherlands). HbA1c levels
were measured with a Tina-quant third-generation
assay on Cobas 6000 analyzer (Roche Diagnostics).
Patients and their general practitioners received a
letter that contained the exact laboratory results and
advice on how to proceed further, based on current
guidelines.
The BIO-RESORT trial complied with the
CONSORT 2010 Statement and Declaration ofand served on the advisory board for Boehringer
arch grant support from Boehringer Ingelheim and
thors have reported that they have no relationships
contributed equally to this work.
6, 2017, accepted October 31, 2017.
TABLE 1 Definitions of Different Metabolic States
OGTT* HbA1c and FPG†
(“Silent”) diabetes FPG $7.0 mmol/l
OR
2-h G $11.1 mmol/l
FPG $7.0 mmol/l
OR
HbA1c $48 mmol/mol
Pre-diabetes
Impaired glucose tolerance FPG <7.0 mmol/l
AND
2-h G 7.8–11.1 mmol/l
Impaired fasting glucose FPG 6.1–6.9 mmol/l
AND
HbA1c 42–47 mmol/mol
Normal G metabolism FPG <6.1 mmol/l AND
2-h G <7.8 mmol/l
FPG <6.1 mmol/l
AND
HbA1c #41 mmol/mol
*Based on the World Health Organization 1999 criteria. †Based on the International Expert
Committee 2009 criteria.
FPG ¼ fasting plasma glucose; G ¼ glucose; HBA1c ¼ glycosylated hemoglobin; OGTT ¼ oral
glucose tolerance testing.
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450Helsinki and was approved by the Medical Ethics
Committee Twente (17). All patients provided writ-
ten informed consent.
DEFINITIONS OF METABOLIC STATES AND STUDY
ENDPOINTS. Definitions of metabolic states were
based on the World Health Association 1999 criteria
for OGTT and the International Expert Committee
2009 criteria for HbA1c with FPG (19,20). Patients were
considered to have normal glucose metabolism if FPG
was <6.1 mmol/l and 2-h glucose levels were <7.8
mmol/l, or HbA1c levels were #41 mmol/mol (Table 1).
Pre-diabetes was defined as either IGT by OGTT or
IFG: FPG level <7.0 mmol/l and 2-h glucose level of
7.8 to 11.0 mmol/l; or FPG level of 6.1 to 6.9 mmol/l
and HbA1c level of 42 to 47 mmol/mol. Patients were
considered diabetics if FPG levels were $7.0 mmol/l
or 2-h glucose levels were $11.1 mmol/l, or if HbA1c
levels were $48 mmol/mol (8,9,19,20).
Of note, HbA1c has been endorsed for DM diagnosis
and screening. In 2009, the International Expert
Committee jointly organized by the American Dia-
betes Association, the International Diabetes Feder-
ation, and the European Association for the Study of
Diabetes recommended HbA1c to be added to the
diagnostic instruments for detecting DM, with the
recommended HbA1c cutoff point of $48 mmol/mol
($6.5%) (19,20).
The pre-specified endpoints of the BIO-RESORT
Silent Diabetes study are based on the Academic
Research Consortium (21) and have been described
previously (17). In brief, the primary endpoint target
vessel failure is a composite of cardiac death, target
vessel–related myocardial infarction (MI), or repeated
target vessel revascularization (components in
hierarchical order). Death was considered cardiac,
unless an unequivocal noncardiac cause could beestablished. MI was defined by any creatine kinase
concentration of more than double the upper limit of
normal with elevated confirmatory cardiac bio-
markers (i.e., troponin or myocardial band fraction of
creatine kinase). Periprocedural MI occurred within
48 h of the PCI procedure. The more global major
adverse cardiac events, consisting of all-cause death,
any MI, emergent coronary artery bypass grafting, or
clinically indicated coronary revascularization, was
also assessed (17).
PERCUTANEOUS INTERVENTION, ANALYSES, AND
MONITORING. The PCI was performed according to
standard techniques, current guidelines, and the
physician’s judgment, as previously described in
detail (17). In general, dual antiplatelet therapy was
prescribed for 6 to 12 months.
Electrocardiograms were systematically assessed.
Laboratory tests included systematic assessment of
cardiac markers after the intervention and subse-
quent serial measurements in case of suspected
ischemia. Clinical follow-up was obtained at visits to
outpatient clinics or, if not feasible, by telephone
follow-up or a medical questionnaire. Study coordi-
nation and data management were performed by the
clinical research organization Cardio Research
Enschede (Enschede, the Netherlands). A formal data
safety monitoring committee reviewed the outcome
data of the main randomized trial periodically. Data
monitoring, processing of clinical outcome data, and
independent clinical event adjudication were per-
formed by an independent clinical research organi-
zation (Diagram, Zwolle, the Netherlands).
STATISTICAL ANALYSIS. For dichotomous and cat-
egorical variables, data were reported as frequencies
and percentages. Continuous variables were
expressed as mean  SD. The time to primary
endpoint and components thereof were assessed ac-
cording to Kaplan-Meier methods; log-rank testing
was applied for between-group comparisons. The
Pearson chi-square test or Fisher exact test were used
to compare categorical variables, and the Student t
test to compare continuous variables. We performed
Cox proportional hazards regression analyses to
investigate the effect of abnormal glucose meta-
bolism on 1-year clinical outcome. The following
variables associated with the primary composite
endpoint were included in the multivariate models:
demographics (sex, age), clinical (hypercholesterole-
mia, statin use, systolic blood pressure, smoking,
body mass index, previous revascularization, previ-
ous MI), laboratory (hemoglobin level at admission,
renal insufficiency). Using forward stepwise selec-
tion, all variables that were significantly different
FIGURE 1 Prevalence of Disturbed Glucose Metabolism in PCI Patients Without Known Diabetes, and Its Impact on Clinical Outcome
Of the study participants, one-third had an abnormal glucose metabolism, of which 7% had silent diabetes mellitus (DM). At 1-year follow-up,
more than one-half of the target vessel failures (TVFs) occurred in patients with abnormal glucose metabolism. Specifically, the 7% silent DM
patients accounted for almost a one-quarter of all adverse events. PCI ¼ percutaneous coronary intervention.
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451remained in the multivariate model, eliminating
variables with a nonsignificant association (p > 0.15)
with the outcome. The final model included age, sex,
hypercholesterolemia, previous MI, and previous
revascularization. All statistical tests were 2-tailed;
p values <0.05 were considered significant. Data an-
alysts remained blinded to the assigned treatment
until the evaluation of 1-year follow-up was finished.
Statistical analyses were performed with SPSS version
22 (IBM Corporation, Armonk, New York).
RESULTS
Of the 988 study participants without known dia-
betes, 330 (33.4%) had an abnormal glucose meta-
bolism based on OGTT or HbA1c with FPG levels, of
whom 71 (7.2%) had silent diabetes (Figure 1). Sole
use of OGTT data resulted in the detection of silent
diabetes in 68 (6.9%) patients and pre-diabetes in
132 (13.4%) patients, whereas 788 (79.8%) patients
had normal glucose tolerance. Based on HbA1c and
FPG, silent diabetes was present in 33 (3.3%)patients and pre-diabetes in 217 (22.0%) patients,
and 738 (74.7%) patients had a normal glucose
metabolism.
Baseline characteristics and procedural details of
patients with silent diabetes, pre-diabetes, and
normal glucose metabolism are presented in Table 2.
Patients with abnormal glucose metabolism had a
slightly higher body mass index, more often a previ-
ous myocardial infarction, and tended to be older
than patients with normal glucose metabolism.
At 1-year follow-up, 21 (6.4%) of the 330 patients
with abnormal glucose metabolism (based on one or
the other diagnostic approach) reached the primary
composite endpoint of target vessel failure (vs. 18
[2.7%] in 658 patients with normal glucose meta-
bolism; p ¼ 0.006). In other words, more than one-
half (54%) of the target vessel failures occurred in the
one-third of study participants who had an abnormal
glucose metabolism; specifically, silent diabetic
patients comprised 7% of the study participants
and accounted for 23% of all target vessel failures
(Figure 1).
TABLE 2 Baseline Characteristics
OGTT-Based Metabolic States
p Value
HbA1c and FPG Metabolic States
p Value
Abnormal Glucose Metabolism
NG
Abnormal Glucose Metabolism
NGSilent DM Pre-DM Silent DM Pre-DM
(n ¼ 68) (n ¼ 132) (n ¼ 788) (n ¼ 33) (n ¼ 217) (n ¼ 738)
Age, yrs 63.9  9.2 62.5  9.8 61.3  10.2 0.08 62.1  8.1 63.1  10.3 61.2  10.1 0.07
Male 53 (77.9) 98 (74.2) 623 (79.1) 0.46 24 (72.7) 179 (82.5) 571 (77.4) 0.20
BMI, kg/m2 28.5  4.5 28.5  3.8 27.0  3.9 <0.001 28.5  4.6 28.3  4.1 27.0  3.9 <0.001
Hypertension 29 (42.6) 64 (48.5) 301 (38.2) 0.07 16 (48.5) 89 (41.0) 289 (39.2) 0.52
Systolic blood pressure, mm Hg 136.2  24.5 139.8  24.8 133.6  23.8 0.02 134.3  21.8 134.8  24.0 134.6  24.2 0.99
Hypercholesterolemia 36 (52.9) 52 (39.4) 331 (42.0) 0.16 15 (45.5) 96 (44.2) 308 (41.7) 0.76
Current smoker 23 (35.4) 39 (30.5) 230 (29.7) 0.63 23 (35.4) 68 (32.4) 213 (29.3) 0.57
Family history of coronary artery disease 31 (49.2) 70 (54.7) 398 (52.4) 0.77 17 (56.7) 109 (52.4) 373 (52.3) 0.90
Previous MI 18 (26.5) 18 (13.6) 127 (16.1) 0.06 11 (33.3) 47 (21.7) 105 (14.2) 0.001
Previous PCI 12 (17.6) 24 (18.2) 111 (14.1) 0.38 7 (21.2) 42 (19.4) 98 (13.3) 0.05
Previous CABG 8 (11.8) 6 (4.5) 46 (5.8) 0.11 3 (9.1) 17 (7.8) 40 (5.4) 0.32
Renal insufficiency* 4 (5.9) 4 (3.0) 13 (1.6) 0.05 1 (3.0) 7 (3.2) 13 (1.8) 0.39
Clinical presentation 0.66 0.97
STEMI 15 (22.1) 42 (31.8) 249 (31.6) 11 (33.3) 65 (30.0) 230 (31.2)
NSTEMI 12 (17.6) 28 (21.2) 147 (18.7) 6 (18.2) 40 (18.4) 141 (19.1)
Unstable angina 17 (25.0) 26 (19.7) 157 (19.9) 8 (24.2) 42 (19.4) 150 (20.3)
Stable angina 24 (35.3) 36 (27.3) 235 (29.8) 8 (24.2) 70 (32.3) 217 (29.4)
Multivessel treatment 16 (23.5) 29 (22.0) 139 (17.6) 0.23 5 (15.2) 45 (20.7) 134 (18.2) 0.60
LAD 30 (44.1) 71 (53.8) 404 (51.3) 0.26 16 (48.5) 100 (46.1) 389 (52.7) 0.22
Total stent length/patient 51.8  34.2 43.8  27.2 43.7  30.0 0.04 48.6  30.0 43.9  30.0 44.2  30.0 0.69
Stents/patient 2.13  1.23 1.94  1.10 1.85  1.14 0.06 2.13  1.23 1.94  1.10 1.85  1.14 0.92
Medication at admission
Statin 49 (72.1) 65 (49.2) 425 (53.9) 0.007 20 (60.6) 126 (58.1) 393 (53.3) 0.36
b-blocker 42 (61.8) 60 (45.5) 393 (49.9) 0.09 16 (48.5) 115 (53.0) 364 (49.3) 0.63
ACE inhibitor 21 (30.9) 24 (18.2) 178 (22.6) 0.13 9 (27.3) 56 (25.8) 158 (21.4) 0.32
CA-antagonist or ARB 22 (32.4) 41 (31.1) 193 (24.5) 0.13 10 (30.3) 75 (34.6) 171 (23.2) 0.003
Aspirin 44 (64.7) 71 (53.8) 454 (57.6) 0.33 18 (54.5) 133 (61.3) 418 (56.6) 0.45
Oral anticoagulant 4 (5.9) 9 (6.8) 46 (5.8) 0.91 2 (6.1) 21 (9.7) 36 (4.9) 0.03
Medication at discharge
Statin 65 (95.6) 121 (91.7) 742 (94.2) 0.45 31 (93.9) 206 (94.9) 691 (93.6) 0.78
b-blocker 59 (86.8) 115 (87.1) 659 (83.6) 0.50 28 (84.8) 187 (86.2) 618 (83.7) 0.68
ACE inhibitor 34 (50.0) 63 (47.7) 434 (55.1) 0.24 20 (60.6) 110 (50.7) 401 (54.3) 0.46
CA-antagonist or ARB 22 (32.4) 44 (33.3) 202 (25.6) 0.11 10 (30.3) 74 (34.1) 184 (24.9) 0.03
Antiplatelet therapy
Aspirin 68 (100) 131 (99.2) 780 (99.0) 0.69 33 (99.1) 215 (99.1) 731 (99.1) 0.85
Clopidogrel 44 (64.7) 89 (67.4) 501 (63.6) 0.69 18 (54.5) 142 (65.4) 474 (64.2) 0.48
Prasugrel or ticagrelor 24 (35.3) 41 (31.1) 287 (36.4) 0.44 15 (45.5) 75 (34.6) 262 (35.5) 0.45
Oral anticoagulant agent 9 (13.2) 13 (9.8) 67 (8.5) 0.40 3 (9.1) 30 (13.8) 56 (7.6) 0.02
Values are mean  SD or n (%). *Estimated glomerular filtration rate of <30 ml/min/1.73 m2 of body surface area or the need for dialysis.
ARB ¼ angiotensin receptor blocker; ACE ¼ angiotensin-converting enzyme; BMI ¼ body mass index; CA ¼ calcium antagonist; CABG ¼ coronary artery bypass grafting; DM ¼ diabetes mellitus; LAD ¼ left
anterior descending artery; MI ¼myocardial infarction; NG ¼ normal glucose metabolism; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction; NSTEMI¼ non–ST-
segment elevation myocardial infarction; other abbreviations as in Table 1.
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452The rate of the primary endpoint was significantly
higher in patients with silent diabetes as compared
with patients with pre-diabetes and normal glucose
metabolism, based on OGTT (13.2% vs. 7.6% vs. 4.8%;
p < 0.001). Primary endpoint rates in metabolic state
groups, based on the HbA1c and FPG levels, were
similar to rates in OGTT-based analyses (12.1% vs.5.5% vs. 3.1%; p ¼ 0.01); the time-to-event curves are
shown in Figure 2 (landmark analysis in Online
Figure 1). Patients with silent diabetes, pre-diabetes,
and normal glucose tolerance also differed in several
other clinical outcome parameters (Table 3).
The incidence of target vessel MI was higher in
patients with silent diabetes than in patients with
FIGURE 2 Kaplan-Meier Curves of Primary Endpoint at 1-Year Follow-Up
Kaplan-Meier curve for the composite endpoint consisting of cardiac death, target vessel-related myocardial infarction, or target vessel
revascularization at 1-year follow-up. *Timing of oral glucose tolerance testing (OGTT). DM ¼ diabetes mellitus; FPG ¼ fasting plasma
glucose; HbA1c ¼ glycosylated hemoglobin; NG ¼ normal glucose metabolism.
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453pre-diabetes and normal glucose metabolism (OGTT-
based metabolic states: 10.3% vs. 3.8% vs. 1.8%,
p < 0.001; HbA1c þ FPG-based metabolic states:
12.1% vs. 3.7% vs. 1.9%, p ¼ 0.001), which was
mainly related to MI occurring within 48 h of the PCI
procedure (p < 0.001). Mortality rates were low for
all 3 patient groups (Table 3). The time-to-event
curves of target vessel MI and target vessel revas-
cularization at 1-year follow-up are displayed in
Figure 3.
Multivariate analyses demonstrated that abnormal
glucose metabolism by one or the other diagnostic
approach independently predicted adverse event risk
(hazard ratio: 2.2; 95% confidence interval: 1.2 to 4.2).
Patients with silent diabetes had a 3- to 4-fold higher
event risk than did patients with a normal glucose
metabolism (Tables 4 and 5).DISCUSSION
MAIN STUDY FINDINGS. Overall, based on one or the
other diagnostic approach, 33% of the 988 study
participants without known diabetes had an
abnormal glucose metabolism, of whom 7% had silent
diabetes. Based on the OGTT findings only, silent
diabetes was detected in 7% of the 988 study partic-
ipants, pre-diabetes in 13%, and normal glucose
metabolism in 80%. The corresponding prevalences
based on the alternative approach for detecting an
abnormal glucose metabolism (HbA1c with FPG levels)
were 3%, 22%, and 75%, respectively.
At 1-year follow-up, 6.4% of all patients with
abnormal glucose metabolism reached the primary
composite endpoint of target vessel failure, whereas
this rate was significantly lower (2.7%) in patients
TABLE 3 Clinical Events at 1-Year Follow-Up (N ¼ 988)
Based on OGTT Log-Rank p Value Based on HbA1c and FPG Log-Rank p Value
Abnormal Glucose
Metabolism
NG
(n ¼ 788) Overall
Silent DM
vs. NG
Pre-DM
vs. NG
Abnormal Glucose
Metabolism
NG
(n ¼ 738) Overall
Silent DM
vs. NG
Pre-DM
vs. NG
Silent DM
(n ¼ 68)
Pre-DM
(n ¼ 132)
Silent DM
(n ¼ 33)
Pre-DM
(n ¼ 217)
TVF (primary endpoint) 9 (13.2) 8 (6.1) 22 (2.8) <0.001 <0.001 0.05 4 (12.1) 12 (5.5) 23 (3.1) 0.01 0.005 0.09
Death 1 (1.5) 0 (0) 2 (0.3) 0.17 0.10 0.56 0 (0) 1 (0.5) 2 (0.3) 0.86 1.00 0.66
Cardiac death 1 (1.5) 0 (0) 0 (0) 0.001 0.001 — 0 (0) 1 (0.5) 0 (0) 0.17 — 0.07
Any MI 7 (10.3) 5 (3.8) 14 (1.8)* <0.001 <0.001 0.13 4 (12.1) 8 (3.7) 14 (1.9)* 0.001 <0.001 0.12
Periprocedural MI 7 (10.3) 5 (3.8) 12 (1.5) <0.001 <0.001 0.08 4 (12.1) 8 (3.7) 12 (1.6) <0.001 <0.001 0.06
Target vessel MI 7 (10.3) 5 (3.8) 14 (1.8) <0.001 <0.001 0.13 4 (12.1) 8 (3.7) 14 (1.9) 0.001 <0.001 0.12
Q-wave 0 (0) 0 (0) 2 (0.3) 0.001 0.001 0.56 0 (0) 0 (0) 2 (0.3) 0.71 1.00 1.00
Non–Q-wave 7 (10.3) 5 (3.8) 12 (1.6) <0.001 <0.001 0.08 4 (12.1) 8 (3.7) 12 (1.8) 0.001 <0.001 0.06
Revascularization, any 3 (4.4) 6 (4.5) 25 (3.2) 0.65 0.57 0.42 0 (0) 10 (4.6) 24 (3.3) 0.35 0.42 0.34
Target vessel revascularization 3 (4.4) 3 (2.3) 11 (1.4) 0.16 0.06 0.45 0 (0) 5 (2.3) 12 (1.6) 0.59 0.46 0.51
MACE 9 (13.2) 7 (5.3) 22 (2.8) <0.001 <0.001 0.12 4 (12.1) 12 (5.5) 22 (3.0) 0.008 0.003 0.07
Values are n (%). The primary endpoint target vessel failure consists of cardiac death, target vessel myocardial infarction, or target vessel revascularization. Major adverse cardiac events (MACE) consisted of
any death, any MI, emergent CABG, or clinically indicated coronary revascularization. *Two patients experienced a myocardial infarction due to a definite stent thrombosis. Of all of the myocardial infarctions,
none was fatal.
TVF ¼ target vessel failure; other abbreviations as in Tables 1 and 2.
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454with normal glucose metabolism. In other words,
more than one-half (54%) of the target vessel failures
occurred in the one-third of study participants who
had an abnormal glucose metabolism; specifically,
silent diabetic patients comprised 7% of the study
participants and accounted for 23% of all primary
endpoints. This was primarily driven by target vessel
MI, which mainly occurred within 48 h of the index
PCI. Multivariate analyses demonstrated that the
presence of silent diabetes, diagnosed by either OGTT
or HbA1c with FPG, independently predicted the risk
of reaching the primary endpoint.
The findings of the prospective BIO-RESORT Silent
Diabetes study underline the importance of previ-
ously unknown (and untreated) diabetes for clinical
outcome after PCI, performed with contemporary DES
that recently demonstrated excellent safety and effi-
cacy (17). Significantly, the study was performed in a
predominantly white European population in the
Netherlands—a country that has a lower prevalence of
diabetes than the United States and many other Eu-
ropean countries (22), and a health system that is
characterized by a fine-meshed net of primary care
that offers screening for several common diseases,
including diabetes. Therefore, it is fair to assume that
the proportion of silent diabetics among PCI patients
may be higher than 7%, both in countries with a
higher diabetes risk or more difficult access to pri-
mary care.
PREVIOUS STUDIES. There is a lack of OGTT-based
studies investigating the metabolic state and theprevalence of silent diabetes among all-comer pa-
tients undergoing PCI. The German Silent Diabetes
study, which performed OGTT in a more heteroge-
neous population of 1,015 “nondiabetic” patients who
all underwent coronary angiography but differed
significantly regarding the presence and the severity
of coronary artery disease, identified silent diabetes
in 14% and IGT in 34% of patients (16). Data on 3-year
mortality were available in 87.3% of study patients,
showing no significant difference in the proportion of
silent diabetes at baseline among survivors of 3-year
follow-up versus patients who had died (14.1% vs.
19.7%; p ¼ 0.26) (23).
In addition, some previous studies in broad pop-
ulations of PCI patients used HbA1c instead of OGTT
to identify silent diabetics (13,24,25). Of 445
“nondiabetic” patients in the TWENTE trial who had
HbA1c measurements, 10% were classified as having
silent diabetes and showed a higher risk of peri-
procedural MI following the implantation of second-
generation DES (13). Furthermore, a study from
Israel in 760 PCI patients found 29% HbA1c-diagnosed
silent diabetics; in that study silent diabetes was
independently associated with a 1.4-fold increase in
the risk of major cerebrovascular and cardiovascular
endpoints at 1-year follow-up (24).
Several previous studies focused on specific sub-
sets of PCI patients, such as patients undergoing
elective PCI or experiencing non–ST-segment eleva-
tion MI or ST-segment elevation MI (25–28). All of
these studies used diagnostic approaches other than
OGTT to assess the metabolic state. A recent study
FIGURE 3 Kaplan-Meier Curves at 1-Year Follow-Up
Kaplan-Meier curves for (A) target vessel myocardial infarction and (B) target vessel revascularization at 1-year follow-up. *Timing of OGTT.
Abbreviations as in Figure 2.
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TABLE 5
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TABLE 4 Clinical Events in Metabolic States Based on OGTT Classifications (N ¼ 988)
OGTT-Based Classification Unadjusted HR (95% CI) Adjusted HR* (95% CI)
Abnormal Glucose
Metabolism
NG
(n ¼ 788)
Silent DM
vs. NG
Pre-DM
vs. NG
Silent DM
vs. NG
Pre-DM
vs. NG
Silent DM
(n ¼ 69)
Pre-DM
(n ¼ 132)
TVF (primary endpoint) 9 (13.2) 8 (6.1) 22 (2.8) 5.00 (2.30–10.87) 2.20 (0.98–4.94) 4.21 (1.93–9.21) 2.27 (1.00–5.13)
Death 1 (1.5) 0 (0) 2 (0.3) 0.17 (0.02–1.89) — — —
Cardiac death 1 (1.5) 0 (0) 0 (0) — — — —
Any MI 7 (10.3) 5 (3.8) 14 (1.8) 5.95 (2.40–14.74) 2.14 (0.77–5.93) 4.79 (1.92–11.96) 2.14 (0.77–5.97)
Periprocedural MI 7 (10.3) 5 (3.8) 12 (1.5) 6.89 (2.71–17.51) 2.49 (0.88–7.06) 5.55 (2.16–14.22) 2.43 (0.85–6.92)
Target vessel MI 7 (10.3) 5 (3.8) 14 (1.8) 5.95 (2.40–14.74) 2.14 (0.77–5.93) 4.79 (1.92–11.96) 2.14 (0.77–5.97)
Revascularization 3 (4.4) 6 (4.5) 25 (3.2) 1.41 (0.43–4.68) 1.45 (0.59–3.53) 1.43 (0.43–4.79) 1.49 (0.61–3.65)
Target vessel revascularization 3 (4.4) 3 (2.3) 11 (1.4) 3.23 (0.90–11.58) 1.64 (0.46–5.87) 2.82 (0.77–10.30) 1.78 (0.49–6.50)
MACE 9 (13.2) 7 (5.3) 22 (2.8) 5.00 (2.30–10.88) 1.92 (0.82–4.50) 4.25 (1.94–9.28) 1.94 (0.82–4.58)
Values are n (%) unless otherwise indicated. The primary endpoint (TVF) consists of cardiac death, target vessel MI, or target vessel revascularization. MACE consists of any death, any MI,
emergent CABG, or clinically indicated coronary revascularization. *Adjusted by use of multivariate Cox proportional hazards model (including age, sex, hypercholesterolemia, previous MI, and
previous revascularization).
CI ¼ confidence interval; HR ¼ hazard ratio; other abbreviations as in Tables 1 to 3.
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456from the United States in patients with ST-segment
elevation MI identified silent diabetes in 9.2%; both
in-hospital and 3-year mortality of patients with si-
lent diabetes were found to be significantly increased
(25). A study in 500 elective PCI patients with HbA1c
levels <7.0% showed that an HbA1c between 6% and
7% independently predicted cardiovascular events
(26). Another study from the United States identified
14% patients with silent diabetes based on abnormal
FPG levels among PCI patients with acute coronary
syndromes and showed silent diabetes to indepen-
dently predict mortality (27). A rate of 18% silent di-
abetics was reported by another group, showing a
significant relation with medium-term follow-up afterClinical Events Including HRs in Metabolic States Based on HbA1c and F
HbA1c þ FPG-Based Classification Una
Abnormal Glucose
Metabolism
NG
(n ¼ 738)
Silent D
vs. N
Silent DM
(n ¼ 33)
Pre-DM
(n ¼ 217)
ary endpoint) 4 (12.1) 12 (5.5) 20 (2.7) 4.09 (1.41–
0 (0) 1 (0.5) 2 (0.3) —
death 0 (0) 1 (0.5) 0 (0) —
4 (12.1) 8 (3.7) 14 (1.9) 6.55 (2.16–
edural MI 4 (12.1) 8 (3.7) 12 (1.6) 7.57 (2.44–
essel MI 4 (12.1) 8 (3.7) 14 (1.9) 6.55 (2.16–
rization 0 (0) 10 (4.6) 24 (3.3) —
essel revascularization 0 (0) 5 (2.3) 12 (1.6) —
4 (12.1) 12 (5.5) 22 (3.0) 4.27 (1.47–
(%) unless otherwise indicated. The primary endpoint (TVF) consists of cardiac death, targ
ABG, or clinically indicated coronary revascularization. *Adjusted by use of multivariate Cox p
ascularization).
ions as in Tables 1–4.PCI (28). Nevertheless, most of the aforementioned
studies examined patients who were treated with
balloon angioplasty or bare-metal stents (26–28)—
techniques and devices that have been greatly
replaced by PCI with implantation of contemporary
DES. More recently, a study in 4,176 Dutch patients
with ST-segment elevation MI showed that elevated
HbA1c levels were independently associated with
mortality, but the prevalence and clinical outcome of
patients with silent diabetes were not reported (29).
IMPLICATIONS. Our findings suggest that screening
for abnormal glucose metabolism may be advisable,
as it was associated with an increased adverse eventPG Classifications
djusted HR (95% CI) Adjusted HR* (95% CI)
M
G
Pre-DM
vs. NG
Silent DM
vs. NG
Pre-DM
vs. NG
11.83) 1.80 (0.90–3.61) 3.31 (1.13–9.70) 1.65 (0.82–3.33)
1.70 (0.15–18.78) — 1.85 (0.17–20.64)
— — —
19.91) 1.96 (0.82–4.67) 5.38 (1.75–16.62) 1.83 (0.76–4.40)
23.46) 2.28 (0.93–5.58) 6.24 (1.98–19.69) 2.17 (0.88–5.36)
19.91) 1.96 (0.82–4.67) 5.38 (1.75–16.62) 1.83 (0.76–4.40)
1.43 (0.68–2.98) — 1.37 (0.65–2.88)
1.42 (0.50–4.03) — 1.24 (0.43–3.54)
12.39) 1.88 (0.93–3.80) 3.50 (1.19–10.30) 1.75 (0.86–3.56)
et vessel MI, or target vessel revascularization. MACE consists of any death, any MI,
roportional hazards model (including age, sex, hypercholesterolemia, previous MI, and
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457risk—in particular of periprocedural MI. The lipid-rich
plaque composition and the hypercoagulable state
augment the atherothrombotic risk in patients with
hyperglycemia and diabetes (7,11), and might have
contributed to our findings. Others have also postu-
lated that pre-diabetes poses an increased risk for
cardiovascular events, justifying efforts to improve
glucose metabolism and delay conversion to diabetes
(10,30). Future studies should evaluate approaches
aiming at early detection of silent diabetes and pre-
diabetes in patients undergoing PCI and ways to
reduce their increased adverse event rates. As
recently confirmed by the PARIS (Patterns of Non-
Adherence to Anti-Platelet Regimens in Stented
Patients) registry the presence of DM is associated
with increased thrombotic but not bleeding events,
thereby reinforcing the potential need for longer or
more potent platelet inhibition in such patients (31).
In this context, it will be important to take into ac-
count the increased platelet reactivity in diabetics
(32) who have shown a reduced sensitivity to anti-
platelet drugs (33).
DIAGNOSTIC TESTS TO DETECT ABNORMAL
GLUCOSE METABOLISM. OGTT is an established
approach to assess glucose metabolism and has
detected more patients with DM in the general pop-
ulation as well as in patients with coronary disease
(14,34). On the other hand, assessment of HbA1c rep-
resents a straightforward, robust, and cheap diag-
nostic test that is more convenient, as it can be done
in the nonfasting state, and it showed in previous
studies a higher pre-analytical stability and lower
measurement variation (13). The fact that HbA1c is not
affected by acute, stress-related effects on glucose
metabolism makes it more reliable than fasting
glucose in the acute setting and particularly valuable
to detect abnormal glucose metabolism in patients
with acute coronary syndromes (35). Nevertheless, as
both diagnostic tests do not necessarily detect the
same individuals with abnormal glucose metabolism,
they may be complementary rather than competitive.
In fact, in an “ideal world” without financial and
logistic constraints, it may be of value to assess FPG,
2 h post-load glucose and HbA1c levels in patients who
undergo PCI. However, conducting OGTT is much
more labor intensive and onerous on patients, and
thus more difficult to integrate into routine clinical
practice.
Of further note, patients with diabetes and estab-
lished cardiovascular disease have recently beenshown to substantially benefit in terms of reduced
cardiovascular mortality ($20% reductions) from
newer diabetes agents, such as empagliflozin and
liraglutide, as recently reviewed (36). Thus, detecting
silent diabetes may allow more patients to potentially
benefit from such therapies sooner. Such testing
would also allow better emphasis of and stronger
encouragement and support toward positive lifestyle
changes to mitigate diabetes development in patients
newly identified with pre-diabetes.
STUDY LIMITATIONS. Although we almost reached
our initial goal of performing OGTT in 1,000 patients,
we cannot exclude that somewhat healthier in-
dividuals agreed to participate. OGTT was performed
4 to 6 weeks after the index PCI and therefore after
the occurrence of any periprocedural events, which
excluded patients with PCI-related lethal events. It is
unlikely, but cannot be entirely ruled out, that
reverse causality might have played a role in the
prevalence of silent diabetes in patients who experi-
enced periprocedural events. The timing of OGTT was
chosen based on logistic reasons and to avoid any
disturbance caused by procedure- and disease-related
stress or repair processes after an MI. Data were ob-
tained from patients treated in a single PCI center;
however, this high-volume tertiary PCI center was the
highest enrolling site in the BIO-RESORT trial, and it
exclusively serves an entire region in the east of the
Netherlands, which ensured an unselected referral of
patients from a large region. All aspects taken
together may explain the overall low incidence of
clinical events, which is why the results of this study
should be considered hypothesis generating only.
CONCLUSIONS
Abnormal glucose metabolism was detected in 1 of 3
“nondiabetic” PCI patients and was independently
associated with a significantly higher event risk. Si-
lent diabetes, either detected by OGTT or HbA1c and
FPG, independently predicted worse short-term and
1-year clinical outcomes after treatment with
contemporary DES. Future intervention trials should
determine whether meaningful benefits accrue from
routine glycemia testing in such patients.
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PERSPECTIVES
WHAT IS KNOWN? Diabetic patients have a higher
adverse events risk and continue to show a higher
mortality despite the development of newer-generation
DES. Undetected and thus untreated (silent) diabetes
may increase event risks after PCI with contemporary
drug-eluting stents.
WHAT IS NEW? The BIO-RESORT Silent Diabetes study
is the first large-scale study to (also) use OGTT in an
all-comer population of “nondiabetic” patients who
underwent PCI. The study underlines the importance of
silent diabetes and pre-diabetes for post-PCI clinical
outcome in all-comers treated with contemporary
thin-strut DES. Screening for abnormal glucose
metabolism among PCI patients without previously
known diabetes is advisable, as it allows identifying
subjects at an increased event risk.
WHAT IS NEXT? Knowledge about the prevalence of
abnormal glucose metabolism among PCI all-comers
and the timing of their adverse events is of great
importance for developing concepts and future studies
aiming at a risk reduction. It may also allow more patients
to benefit from newer diabetes therapies with proven
benefits in patients with diabetes plus coronary artery
disease.
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